The estimated Net Worth of Elizabeth H.Z. Thompson is at least $2.56 Million dollars as of 30 December 2022. Elizabeth Thompson owns over 19,055 units of IGM Biosciences stock worth over $305,522 and over the last 3 years Elizabeth sold IGMS stock worth over $2,256,035.
Elizabeth has made over 7 trades of the IGM Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently Elizabeth exercised 19,055 units of IGMS stock worth $223,706 on 30 December 2022.
The largest trade Elizabeth's ever made was exercising 19,055 units of IGM Biosciences stock on 30 December 2022 worth over $223,706. On average, Elizabeth trades about 4,457 units every 36 days since 2021. As of 30 December 2022 Elizabeth still owns at least 26,024 units of IGM Biosciences stock.
You can see the complete history of Elizabeth Thompson stock trades at the bottom of the page.
Elizabeth's mailing address filed with the SEC is C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO, CA, 92130.
Over the last 5 years, insiders at IGM Biosciences have traded over $2,263,330 worth of IGM Biosciences stock and bought 10,358,723 units worth $195,788,133 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Group, Llc Green Jeremy Red... und Bros. Advisors Lp667, L.P.B.... On average, IGM Biosciences executives and independent directors trade stock every 13 days with the average trade being worth of $942,182. The most recent stock trade was executed by Julie Hambleton on 25 July 2024, trading 15,132 units of IGMS stock currently worth $21,033.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
IGM Biosciences executives and other stock owners filed with the SEC include: